Asgharian, B; Turner, ML; Gibril, F; Entsuah, LK; Serrano, J; Jensen, RT (November 2004). “Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1.”. 《The Journal of Clinical Endocrinology and Metabolism》 89 (11): 5328–36. doi:10.1210/jc.2004-0218. PMID15531478.
Dora JM, Siqueira DR, Meyer EL, Punales MK, Maia AL (November 2008). “Pancreatitis as the first manifestation of multiple endocrine neoplasia type 2A”. 《Arq Bras Endocrinol Metabol》 52 (8): 1332–6. doi:10.1590/S0004-27302008000800021. PMID19169490.
Sipple JH (1961). “The association of pheochromocytoma with carcinoma of the thyroid gland”. 《Am. J. Med.》 31: 163–6. doi:10.1016/0002-9343(61)90234-0.
dovepress.com
[1]Archived 2012년 5월 23일 - 웨이백 머신 123I labeled metaiodobenzylguanidine for diagnosis of neuroendocrine tumors. Jiang L, Schipper ML, Li P, Cheng Z, Reports in Medical Imaging. 2009: 2 79-89
Asgharian, B; Turner, ML; Gibril, F; Entsuah, LK; Serrano, J; Jensen, RT (November 2004). “Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1.”. 《The Journal of Clinical Endocrinology and Metabolism》 89 (11): 5328–36. doi:10.1210/jc.2004-0218. PMID15531478.
Dora JM, Siqueira DR, Meyer EL, Punales MK, Maia AL (November 2008). “Pancreatitis as the first manifestation of multiple endocrine neoplasia type 2A”. 《Arq Bras Endocrinol Metabol》 52 (8): 1332–6. doi:10.1590/S0004-27302008000800021. PMID19169490.
Martino Ruggieri (2005). 《Neurocutaneous Disorders : The Phakomatoses》. Berlin: Springer. ISBN3-211-21396-1. - Chapter: Multiple Endocrine Neoplasia Type 2B by Electron Kebebew, Jessica E. Gosnell and Emily Reiff. Pages 695-701. [2][깨진 링크(과거 내용 찾기)] This reference quotes a prevalence of 1 in 40,000, but this figure is inconsistent with the same reference's calculated incidence of 4 per 100 million per year for MEN2B.
[1]Archived 2012년 5월 23일 - 웨이백 머신 123I labeled metaiodobenzylguanidine for diagnosis of neuroendocrine tumors. Jiang L, Schipper ML, Li P, Cheng Z, Reports in Medical Imaging. 2009: 2 79-89
Martino Ruggieri (2005). 《Neurocutaneous Disorders : The Phakomatoses》. Berlin: Springer. ISBN3-211-21396-1. - Chapter: Multiple Endocrine Neoplasia Type 2B by Electron Kebebew, Jessica E. Gosnell and Emily Reiff. Pages 695-701. [2][깨진 링크(과거 내용 찾기)] This reference quotes a prevalence of 1 in 40,000, but this figure is inconsistent with the same reference's calculated incidence of 4 per 100 million per year for MEN2B.